Abstract
Migraine is among the most common chronic disorders in the developed countries, affecting up to 17% of adult women and 6% of adult men. It is also among the chronic disorders most commonly associated with recurring absence from work. It has been estimated that in the United States the indirect annual societal cost of migraine, mostly as lost work, is US$12 billion. Migraine diagnosis and treatment is hindered by the lack of reliable serum or genetic biomarkers that could potentially improve treatment choices. Research programs focused on identifying and developing migraine biomarkers for both prevention and treatment must be included in the national biomedical research agenda.
| Original language | English |
|---|---|
| Pages (from-to) | 267-269 |
| Number of pages | 3 |
| Journal | Drug Development Research |
| Volume | 68 |
| Issue number | 6 |
| DOIs | |
| State | Published - Sep 2007 |
Keywords
- Angiotensin-converting enzyme
- Direct costs
- Indirect costs
- Migraine biomarkers
- National Institute of Neurological Disorders and Stroke
- Plasma calcitonin gene-related peptide (CGRP)
- Tumor necrosis factor-α (TNF-α)